CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02154672
NCT02154672N/ACompleted

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Yale University·observational·Posted Jun 3, 2014·Updated Feb 9, 2021

In Brief

An observational study for Prostate Cancer. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 3, 2014
Enrollment StartMay 1, 2014
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 12.1 years ago